124 related articles for article (PubMed ID: 4828533)
1. Immunotherapy of malignant melanoma with vaccinia virus.
Roenigk HH; Deodhar S; St Jacques R; Burdick K
Arch Dermatol; 1974 May; 109(5):668-73. PubMed ID: 4828533
[No Abstract] [Full Text] [Related]
2. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
3. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
[No Abstract] [Full Text] [Related]
4. [The treatment of advanced malignant melanoma with vaccina oncolysates (author's transl)].
Wallack MK
Nouv Presse Med; 1979 May; 8(23):1919-21. PubMed ID: 223123
[TBL] [Abstract][Full Text] [Related]
5. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.
Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A
Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176
[TBL] [Abstract][Full Text] [Related]
6. [The treatment of melanoma metastases with smallpox vaccine and Freund's adjuvant].
Herrmann WP; Tritsch H
Munch Med Wochenschr; 1970 Oct; 112(42):1916. PubMed ID: 5536277
[No Abstract] [Full Text] [Related]
7. Microcytotoxicity and serum blocking factors in malignant melanoma and halo nevus.
Roenigk HH; Deodhar SD; Krebs JA; Barna B
Arch Dermatol; 1975 Jun; 111(6):720-5. PubMed ID: 1094959
[TBL] [Abstract][Full Text] [Related]
8. An investigation of the effects of inoculated and intralymphatic vaccinia virus on primary and secondary deposits of malignant melanoma.
Dent RI; Cruickshank JG; Gordon JA; Swanepoel R
Cent Afr J Med; 1972 Sep; 18(9):173-6. PubMed ID: 4650359
[No Abstract] [Full Text] [Related]
9. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
10. Persistence of cell-mediated immunity to vaccinia virus.
Kim SH; Oh MD
J Infect Dis; 2007 Sep; 196(5):805-6. PubMed ID: 17674329
[No Abstract] [Full Text] [Related]
11. [Oncolysis in lymph-node metastases of melanoma].
Tritsch H
Dtsch Med Wochenschr; 1970 Nov; 95(48):2432-3. PubMed ID: 5480264
[No Abstract] [Full Text] [Related]
12. [Regression of melanoma metastases after immunological therapy].
Malek-Mansour S; Castermans-Elias S; Lapière CM
Dermatologica; 1973; 146(3):156-62. PubMed ID: 4717482
[No Abstract] [Full Text] [Related]
13. Non-specific and specific immunotherapy in patients with melanoma.
Seigler HF; Shingleton WW; Metzgar RS; Buckley CE; Bergoc PM; Miller DS; Fetter BF; Phaup MB
Surgery; 1972 Jul; 72(1):162-74. PubMed ID: 4555924
[No Abstract] [Full Text] [Related]
14. Neuraminidase immunotherapy of tumors in man.
Rosato FE; Brown AS; Miller EE; Rosato EF; Mullis WF; Johnson J; Moskovitz A
Surg Gynecol Obstet; 1974 Nov; 139(5):675-82. PubMed ID: 4428323
[No Abstract] [Full Text] [Related]
15. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
16. [Cutaneous, cellular immunity in malignant melanoma].
Kehrer HC
Wien Klin Wochenschr; 1991; 103(13):396-7. PubMed ID: 1897233
[No Abstract] [Full Text] [Related]
17. Current concepts in the management of malignant melanoma.
Lichtenfeld JL
Am J Med Sci; 1976; 272(2):185-95. PubMed ID: 1008080
[No Abstract] [Full Text] [Related]
18. Use of vaccinia virus in the treatment of metastatic malignant melanoma.
Hunter-Craig I; Newton KA; Westbury G; Lacey BW
Br Med J; 1970 May; 2(5708):512-5. PubMed ID: 4913781
[TBL] [Abstract][Full Text] [Related]
19. Determination of immunity to vaccinia virus by using diluted inactivated vaccinia vaccine solution for skin testing.
Somekh E; Smetana Z; Tanay A; Dalal I; Babai I; Mendelson E
Vaccine; 2004 Dec; 23(3):321-4. PubMed ID: 15530675
[TBL] [Abstract][Full Text] [Related]
20. [New therapeutic experiments in metastasizing melanoma].
Gartmann H
Hippokrates; 1970 Dec; 41(4):532-4. PubMed ID: 5496347
[No Abstract] [Full Text] [Related]
[Next] [New Search]
